Annonce • Jun 30
Enhanced Launches the Thor Protocol Product Stack on Its Live Enhanced Platform Enhanced had announced the launch of its Thor Protocol, a comprehensive, clinician-supervised performance product stack available exclusively through its Live Enhanced consumer platform. The Thor Protocol is designed to help consumers support their strength, recovery, and physical performance under the guidance of licensed clinicians. The stack reflects the same evidence-based, medically supervised philosophy that has defined Enhanced's approach to elite athlete performance. Thor’s Protocol includes three clinician-prescribed products, each personalized to the individual’s lab results and health profile. Testosterone levels decline with age. Published research shows that clinician-supervised testosterone therapy helps support lean body composition, energy, and vitality in men that qualify. Long-term data show favorable effects on body composition, mood, and metabolic markers when levels are maintained within the physiological range. Thor’s protocol starts with baseline bloodwork, with dosing matched to individual needs and monitored over time. NAD+ is a coenzyme central to cellular energy metabolism. Levels decline naturally with age, and research suggests that supporting NAD+ levels helps support cellular energy production and healthy aging. A 2025 study in Nature detailed NAD+’s role in mitochondrial function and cellular resilience, and preclinical research has shown that restoring NAD+ levels supports energy production and supports markers associated with healthy aging. The Enhanced NAD+ protocol is clinician-supervised, with dosage matched to the individual. Daily low-dose tadalafil supports healthy blood flow by promoting nitric oxide-mediated vasodilation. Clinical research supports improvements in endothelial function and vascular tone, with trials reporting better circulation and improved endothelial function. The protocol is clinician-supervised with daily dosing personalized to the individual. For strength athletes, the problem isn’t one system slowing down. It’s multiple systems declining at the same time: hormonal output, cellular energy, vascular function. Thor’s Protocol is intended to address these areas through individualized clinician-guided treatment. Testosterone supports the hormonal foundation. NAD+ supports cellular energy production and recovery at the mitochondrial level. Tadalafil supports blood flow and vascular function. Individually, each addresses a real gap. Together, the protocol addresses multiple physiological systems through individualized clinician-guided care. Every protocol starts with a clinician review by a licensed clinician through Enhanced’s healthcare provider partners. Every protocol is monitored over time, and adjusted as the individual’s data changes. This is not a one-size-fits-all stack off a shelf. It’s a clinician-guided protocol matched to the consumer's physiology. Thor's Protocol is available now exclusively through the Live Enhanced platform. Clinician-prescribed products require a consultation with a licensed provider through the platform. Board Change • Jun 29
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Director Jim Simpson is the most experienced director on the board, commencing their role in 2026. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Annonce • Jun 15
Enhanced Group Inc. announced that it expects to receive $49.999991 million in funding from Apeiron Investment Group Limited Enhanced Group Inc. announced that it has entered into an agreement to issue 12,853,468 shares of its Class A common stock (the "Common Stock") at a purchase price per share equal to $3.89 per share and 12,853,468 warrants to purchase Common Stock with an exercise price of $3.89 per share for the gross proceeds of $50 million. The initial tranche of the PIPE is expected to close on or about June 17, 2026 with the remaining two tranches in aggregate expected to close within forty-five days of the initial closing, in each case subject to satisfaction of customary closing conditions. The Private Placement is expected to close in three tranches, with approximately $25.0 million of the gross proceeds expected to close on or about June 17, 2026 (the “First Closing”), approximately $11.75 million of the gross proceeds expected to close on or about June 22, 2026 and the remaining approximately $13.25 million of the gross proceeds in third tranche. The transaction involves participation of Apeiron Investment Group Limited and Maximilian Martin, Chief Executive Officer of the Company and a member of the Board of Directors of the Company as an investors. Annonce • May 22
Enhanced Group, Inc. Provides Clinical Trial Update for Enhanced Medical Program Enhanced, announced that its Institutional Review Board (IRB) approved clinical study has been posted for review to ClinicalTrials.gov. The study is part of the Enhanced Medical Program, which gives athletes the opportunity to consider FDA-approved substances, prescribed by doctors as part of the study, and continuous medical screenings to explore enhancements in the safest possible manner. The interventional phase of the trial has now concluded, with the five-year observational monitoring period now commencing. The trial can be located on ClinicalTrials.gov by typing the study acronym "ASCEND001" into the 'other terms' search bar on the homepage. Alternatively, viewers can enter the study's title "Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes" as a search cue. With the inaugural Enhanced Games fast approaching on Sunday May 24th (8:30pm EDT/5:30pm PDT) in Las Vegas, the company also announced preliminary details regarding approved substance usage by athletes during the 12-week trial period. The company will not be commenting further on these aggregate totals until the scheduled Enhanced Games press conference on Saturday May 23rd (1:15pm PST) before the approximately 200 credentialed media from 20 different countries who are expected in attendance. The clinical trial encompassed 36 of the 42 athletes competing. Of those 36 athletes, 2 are competing naturally. Six athletes did not participate in the study with two of those six competing naturally. Athletes participating in the study were permitted to consider substances across five approved categories, including testosterone esters, anabolic agents, peptides and growth factors, metabolic modulators, and stimulants. Only legal substances under U.S. Food & Drug Administration (FDA) guidelines were studied. No peptides currently on the FDA's Category 2 banned list were included in the research. With the interventional period now concluded, Enhanced is releasing aggregate information reflecting the substances incorporated into each athlete's personalized protocols. Individual athlete protocols will not be made publicly available by Enhanced. According to aggregate data collected in the lead up to the Games: 91% of athletes used testosterone or testosterone esters; 79% of athletes used human growth hormone (hGH); 62% of athletes used stimulants (eg. Adderall); 50% of athletes used metabolic modulators, primarily ancillary compounds (eg. Anastrozole) which was used alongside anabolic agents to support protocols; 41% of athletes used erythropoietin (EPO); 29% of athletes used an anabolic steroid agent (eg. Deca durabolin); 5% of athletes used hormonal support therapies (eg. hCG). The clinical data generated through this study is proprietary to Enhanced and forms the foundation of the company's competitive moat. No other consumer health platform in the world is designing personalized enhancement protocols informed by IRB-approved elite athlete research. Through the Live Enhanced platform, learnings from elite performance environments will flow directly into individualized consumer protocols, continuously improving product recommendations and personalizing the experience at scale. The primary objective of the study is to assess the safety and tolerability of certain approved medical compounds when administered to adult athletes under individualized medical supervision over a treatment period of up to 25 weeks. Primary endpoints include the incidence of treatment-related adverse events and the proportion of participants who discontinue use due to such events. Secondary objectives include evaluating changes in physiological and performance-related parameters through structured baseline and follow-up assessments. Assessments include cardiology evaluation and imaging, respiratory testing, organ health imaging, body composition analysis, musculoskeletal assessment, neurocognitive screening and biomarker analysis using blood, urine and saliva samples. All participants underwent comprehensive baseline assessments, ongoing medical monitoring during the treatment period, and will receive structured long-term follow-up for up to five years to assess health outcomes. All substances used in the study were approved by relevant health authorities and were procured through regulated pharmaceutical supply chains. Administration, dosages, adjustment, interruption, or discontinuation of any substance were determined by the Principal Investigators based on individualized medical evaluation and in accordance with IRB-approved protocols in collaboration with the independent medical and science commission. Participants participated with full consent and may decline or discontinue participation at any time. The study is sponsored by Enhanced. Clinical oversight and decision-making are the responsibility of the Principal Investigators and were subject to independent monitoring mechanisms, including a Data and Safety Monitoring Board. Board Change • May 18
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
